Trial
NCT04557384
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Advanced Solid Tumor
Intervention
Ramucirumab
Why stopped
Study terminated due to inadequate PK profile associated with the subcutaneous formulation.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-27